In a lab move that could shake up how scientists think about treating Alzheimer’s, UT Southwestern researchers in Dallas say they have redesigned the tau protein so it keeps doing its normal microtubule-binding job while shrugging off the pathological clumping that drives Alzheimer’s and other tauopathies. In lab tests, the engineered tau fragments did not form the threadlike deposits that damage brain cells, and similar anti-aggregation behavior showed up in cultured cells. The study, led by Lukasz Joachimiak’s group, suggests a fresh way to block tau’s toxic assembly without wrecking its day-to-day function in neurons.
Joachimiak and colleagues report that they tweaked only a few amino acids near tau’s aggregation core, coaxing the protein into a rigid, curved hairpin shape that sterically shields the “VQIVYK” amyloid motif and blocks cross-molecule contacts. In biochemical assays, the designer tau still latched onto microtubules, indicating that its physiological role stayed intact even as it resisted forming aggregates. According to UT Southwestern, the findings were published in the journal Structure.
How the Designer Tau Blocks Clumping
The team constructed tau fragments by swapping amino acids between the four-repeat (4R) repeats and the VQIVYK motif to mimic the sequence context of the less-pathogenic three-repeat (3R) isoform, creating a hairpin that buries the amyloid motif. In biochemical aggregation assays, the unmodified fragments readily formed fibrils, while the designer versions did not, indicating that the hairpin keeps VQIVYK motifs on neighboring molecules from making the nucleating contacts that seed fibrils. These structural and cellular findings are described in a Structure paper indexed on PubMed.
Why the VQIVYK Motif Matters
Decades of tau research have spotlighted VQIVYK as a central amyloid-driving sequence and shown that nearby regions and local structure influence whether that core becomes exposed. A 2019 study in Nature Communications found that compact local structures around the motif can keep it inert, and that small sequence or conformational changes can flip it into an aggregation-prone state. That backdrop helps explain why Joachimiak’s hairpin engineering produced such a pronounced biochemical effect.
What’s Next
The Structure paper lists Sofia Bali as first author and documents NIH support for the project, including an F31 fellowship and a larger NIH award that funded the work, according to PubMed. According to UT Southwestern, the next step is to test whether swapping native tau for the designer version can dial down tauopathies in animal models, a key preclinical move toward turning the strategy into a therapy. If those studies confirm a protective effect, the team says the design could open the door to treatments that prevent tau misfolding while preserving the protein’s normal role in neurons.
